Medications for Gastroesophageal Junction Cancer
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Gastroesophageal Junction Cancer.
Found 2 Approved Drugs for Gastroesophageal Junction Cancer
Nivolumab
Brand Names
Opdivo, Opdualag, Opdivo QVANTIG
Nivolumab
Brand Names
Opdivo, Opdualag, Opdivo QVANTIG
Form: Injection
Method of administration: Subcutaneous, Intravenous
FDA approval date: December 22, 2014
Classification: Endoglycosidase
OPDIVO QVANTIG is a combination of nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of: Renal Cell Carcinoma (RCC) adult patients with intermediate or poor risk advanced RCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab.
Xeloda
Generic Name
Capecitabine
Xeloda
Generic Name
Capecitabine
Form: Tablet
Method of administration: Oral
FDA approval date: April 30, 1998
Classification: Nucleoside Metabolic Inhibitor
XELODA (capecitabine) is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen.
Showing 1-2 of 2
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances